AIM:To assess the efficacy and safety of TECA type hybridartificial liver support system(TECA-HALSS)in providingliver function of detoxification,metabolism and physiologyby treating the patients with acute liver failure(ALF).METHODS:The porcine liver cells(1-2)×10~(10) wereseparated from the Chinese small swine and cultured in thebloreoctor of TECA-BALSS at 37.0℃ and circulated throughthe outer space of the hollow fiber tubes in BALSS.The sixliver failure patients with vadous degree of hepatic comawere treated by TECA-HALSS and with conventionalmedicines.The venous plasma of the patients wasseparated by a plasma separator and treated by charcoaladsorbent or plasma exchange.The plasma circulatedthrough the inner space of the hollow fiber tubes of BALSSand mixed with the patients’ blood cells and flew back totheir blood circulation.Some small molecular weightsubstances were exchanged between the plasma andporcine liver cells.Each treatment lasted 6.0-7.0h.Physiological and biochemical parameters were measuredbefore,during and after the treatment.RESULTS:The average of porcine liver cells was(1.0-3.0)×10~(10) obtained from each swine liver using our modifiedenzymatic digestion method.The survival rate of the cellswas 85%-93% by trypan blue stain and AO/PI fluorescentstain.After cultured in TECA-BALSS bioreactor for 6 h,thesurvival rate of cells still remained 70%-85%.At the end ofTECA-HALSS treatment,the levels of plasma NH_3,ALT,TBand DB were significantly decreased.The patients who werein the state of drowsiness or coma before the treatmentimproved their appetite significantly and regainedconsciousness,some petients resumed light physical workon a short period after the trestment.One to two days afterthe treatment,the ratio of PTA increased warkedly.Duringthe treatment,the heart rates,blood pressure,respirationcondition and serum electrolytes(K~+,Na~+ and cr)werestable without thrombosis and bleeding in all the sixpatients.CONCLUSION:TECA-HALSS treatment could be a rapid,safe and efficacious method to provide temporary liversupport for patients with ALF. AIM: To assess the efficacy and safety of TECA type hybridartificial liver support system (TECA-HALSS) in providing liver function of detoxification, metabolism and physiology by treating the patients with acute liver failure (ALF). METHODS: The porcine liver cells (1-2 ) × 10 ~ 10 wereseparated from the Chinese small swine and cultured in thebloreoctor of TECA-BALSS at 37.0 ° C and circulated through the outer space of the hollow fiber tubes in BALSS.The sixliver failure patients with vadous degree of hepatic comawere treated by TECA -HALSS and with conventional medicines. The venous plasma of the patients was installed by a plasma separator and treated by charcoal or sorbent or plasma exchange. The plasma circulated through the inner space of the hollow fiber tubes of BALSS and mixed with the patients’ blood cells and flew back totheir blood Home small molecular weightsubstances were exchanged between the plasma and porcine liver cells. Each treatment lasted 6.0-7.0h.Physiological and biochemical Results were from each swine liver using our modifiedenzymatic digestion method. survival rate of the cells was 85% - 93% by trypan blue stain and AO / PI fluorescent stain. After cultured in TECA-BALSS bioreactor for 6 h, thesurvival rate of cells still remained 70% -85%. At the end of TECA-HALSS treatment, the levels of plasma NH3, ALT , TBand DB were significantly decreased.The patients who were in the state of drowsiness or coma before the treatmentimproved their appetizers significantly and regainedconsciousness, some petients resumed light physical workon a short period after the trestment. One to two days afterthe treatment, the ratio of PTA increased warkedly.During the treatment, the heart rates, blood pressure, respiration condition and serum electrolytes (K ~ +, Na ~ + and cr) were able to be without thrombosis and bleeding in the six patients.CONCLUSION: TECA-HALSS treatment could be arapid, safe and efficacious method to provide temporary liversupport for patients with ALF.